Nasdaq
Anbio Biotechnology Prices $8M IPO
The firm plans to use the proceeds to support its commercialization and R&D activities as well as for working capital and general corporate purposes.
T2 Biosystems Lays off Employees, Inks Consulting Agreements With Top Execs
Following a delisting decision by the Nasdaq Hearings Panel, the firm laid off its workforce and agreed to pay top executives for part-time consulting work.
Nasdaq Panel Delisting T2 Biosystems Stock
The company was in violation of the stock exchange's requirements for the minimum bid price and the market value of listed securities.
Nasdaq Affirms OpGen's Delisting Decision
The molecular diagnostics developer has appealed the decision and said its stock will continue to trade on the OTC markets in the meantime.
T2 Biosystems Receives Delisting Notice From Nasdaq
The company has requested a hearing and paid a $20,000 fee to delay its delisting determination until Jan. 9, 2025.
Oct 15, 2024
Nasdaq to Delist Centogene
Aug 23, 2024
OpGen Shares Suspended From Trading on Nasdaq
Aug 8, 2024
Centogene Delisted From Nasdaq
May 16, 2024
OpGen to Execute 1-for-10 Reverse Stock Split
Apr 24, 2024
Nasdaq Warns OpGen About Overdue 2023 Annual Report
Apr 17, 2024
DermTech Receives Delisting Warning From Nasdaq
Jan 7, 2024